Close
Close

Parsatuzumab (CAT#: TAB-902)

Datasheet
DESCRIPTION CATALOG # SIZE PRICE
Anti-Human EGFL7 Recombinant Antibody TAB-902 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFL7. Parsatuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
  • Target
  • EGFL7
  • Type
  • IgG1 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in WB, ELISA, IP, FC, FuncS, Neut, IF and most other immunological methods.
  • CAS
  • 1312797-14-0
  • Predicted N terminal
  • EVQLVESG
  • Molecular Weight
  • 147.8 kDa
  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

BACKGROUND

  • Introduction
  • Parsatuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
  • Antigen Description
  • Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cells adhesion to the substrate in vitro.
  • Function
  • calcium ion binding;
  • Synonyms
  • EGFL7; EGF-like-domain, multiple 7; epidermal growth factor-like protein 7; ZNEU1; EGF-like protein 7; NOTCH4-like protein; vascular endothelial statin; multiple EGF-like domains protein 7; multiple epidermal growth factor-like domains protein 7; NEU1; VE-STATIN; RP11-251M1.2; MGC111117;

Customer reviews and Q&As    

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us